ABEONA THERAPEUT. DL-01 Net Assets
ABEONA THERAPEUT. DL-01 net assets. Based on the latest financial reports, ABEONA THERAPEUT. DL-01 (PCJ) has net assets worth €159.22 Million EUR (≈ $186.14 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€219.57 Million ≈ $256.70 Million USD) and total liabilities (€60.35 Million ≈ $70.56 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore PCJ net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €159.22 Million |
| % of Total Assets | 72.51% |
| Annual Growth Rate | 39.23% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 136.95 |
Net Assets of ABEONA THERAPEUT. DL-01 (2021–2025)
Net assets of ABEONA THERAPEUT. DL-01 from 2021 to 2025. This chart illustrates how ABEONA THERAPEUT. DL-01's net assets have evolved over time, based on quarterly financial data. See PCJ net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for ABEONA THERAPEUT. DL-01 (2021–2025)
The table below shows the annual net assets of ABEONA THERAPEUT. DL-01 from 2021 to 2025. For live market cap and overall valuation, see ABEONA THERAPEUT. DL-01 market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €159.22 Million ≈ $186.14 Million |
+261.60% |
| 2024-12-31 | €44.03 Million ≈ $51.48 Million |
+196.99% |
| 2023-12-31 | €14.83 Million ≈ $17.33 Million |
-44.60% |
| 2022-12-31 | €26.76 Million ≈ $31.29 Million |
-36.84% |
| 2021-12-31 | €42.37 Million ≈ $49.53 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ABEONA THERAPEUT. DL-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8643500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
ABEONA THERAPEUT. DL-01 Net Assets Breakdown (December 2025)
ABEONA THERAPEUT. DL-01 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €901.29 Million | 566.08% |
| Total Equity | €159.22 Million | 100.00% |
ABEONA THERAPEUT. DL-01 Competitors by Market Cap
The table below lists competitors of ABEONA THERAPEUT. DL-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Dishman Carbogen Amcis Limited
NSE:DCAL
|
$256.13 Million |
|
European Wax Center Inc
NASDAQ:EWCZ
|
$256.18 Million |
|
Pure Cycle Corporation
NASDAQ:PCYO
|
$256.22 Million |
|
Metall Zug AG
SW:METN
|
$256.30 Million |
|
Veedol Corporation Limited
NSE:VEEDOL
|
$256.06 Million |
|
Yantai Yatong Precision Mechanical Corp. A
SHG:603190
|
$256.05 Million |
|
Imagicaaworld Entertainment Limited
NSE:IMAGICAA
|
$255.98 Million |
|
Sportking India Limited
NSE:SPORTKING
|
$255.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ABEONA THERAPEUT. DL-01's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 44,031,000 to 159,216,000, a change of 115,185,000 (261.6%).
- Net income of 71,183,000 contributed positively to equity growth.
- New share issuances of 17,300,000 increased equity.
- Other factors increased equity by 26,702,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €71.18 Million | +44.71% |
| Share Issuances | €17.30 Million | +10.87% |
| Other Changes | €26.70 Million | +16.77% |
| Total Change | €- | 261.60% |
Book Value vs Market Value Analysis
This analysis compares ABEONA THERAPEUT. DL-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.54x to 1.33x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €7.20 | €3.85 | x |
| 2022-12-31 | €1.51 | €3.85 | x |
| 2023-12-31 | €0.56 | €3.85 | x |
| 2024-12-31 | €0.96 | €3.85 | x |
| 2025-12-31 | €2.89 | €3.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ABEONA THERAPEUT. DL-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 44.71%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1223.08%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.38x
- Recent ROE (44.71%) is above the historical average (-162.87%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -200.47% | -2831.20% | 0.04x | 1.88x | €-89.17 Million |
| 2022 | -148.34% | -2807.36% | 0.02x | 2.40x | €-42.37 Million |
| 2023 | -365.49% | -1548.23% | 0.05x | 4.32x | €-55.67 Million |
| 2024 | -144.75% | 0.00% | 0.00x | 2.47x | €-68.14 Million |
| 2025 | 44.71% | 1223.08% | 0.03x | 1.38x | €55.26 Million |
Industry Comparison
This section compares ABEONA THERAPEUT. DL-01's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ABEONA THERAPEUT. DL-01 (PCJ) | €159.22 Million | -200.47% | 0.38x | $256.10 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About ABEONA THERAPEUT. DL-01
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of starga… Read more